The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 28, 2015

Filed:

Nov. 27, 2013
Applicant:

Sanofi, Paris, FR;

Inventors:

Josef Pernerstorfer, Hofheim Langenhein, DE;

Heinz-Werner Kleemann, Bischofsheim, DE;

Matthias Schaefer, Ehringshausen, DE;

Alena Safarova, Tucson, AZ (US);

Marcel Patek, Tucson, AZ (US);

Assignee:

Sanofi, Paris, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/00 (2006.01); A61K 31/44 (2006.01); C07C 235/54 (2006.01); C07C 235/42 (2006.01); C07C 235/84 (2006.01); C07C 255/50 (2006.01); C07C 255/54 (2006.01); C07C 255/57 (2006.01); C07C 307/10 (2006.01); C07C 317/46 (2006.01); C07D 213/16 (2006.01); C07D 213/69 (2006.01); C07D 213/81 (2006.01); C07D 213/82 (2006.01); C07D 231/12 (2006.01); C07D 305/04 (2006.01); C07D 305/06 (2006.01); C07D 309/04 (2006.01); C07D 309/08 (2006.01); C07D 313/04 (2006.01); C07D 317/06 (2006.01); C07D 317/68 (2006.01); C07D 317/72 (2006.01); C07D 333/16 (2006.01); C07D 335/14 (2006.01); C07D 335/18 (2006.01); C07D 493/10 (2006.01); C07C 231/00 (2006.01); C07C 231/02 (2006.01); C07D 213/64 (2006.01); C07D 231/18 (2006.01); C07D 305/08 (2006.01); C07D 309/14 (2006.01); C07D 333/32 (2006.01); C07D 335/02 (2006.01);
U.S. Cl.
CPC ...
C07C 235/54 (2013.01); C07C 235/42 (2013.01); C07C 235/84 (2013.01); C07C 255/50 (2013.01); C07C 255/54 (2013.01); C07C 255/57 (2013.01); C07C 307/10 (2013.01); C07C 317/46 (2013.01); C07D 213/16 (2013.01); C07D 213/69 (2013.01); C07D 213/81 (2013.01); C07D 213/82 (2013.01); C07D 231/12 (2013.01); C07D 305/04 (2013.01); C07D 305/06 (2013.01); C07D 309/04 (2013.01); C07D 309/08 (2013.01); C07D 313/04 (2013.01); C07D 317/06 (2013.01); C07D 317/68 (2013.01); C07D 317/72 (2013.01); C07D 333/16 (2013.01); C07D 335/14 (2013.01); C07D 335/18 (2013.01); C07D 493/10 (2013.01); C07C 231/00 (2013.01); C07C 231/02 (2013.01); C07D 213/64 (2013.01); C07D 231/18 (2013.01); C07D 305/08 (2013.01); C07D 309/14 (2013.01); C07D 333/32 (2013.01); C07D 335/02 (2013.01); C07C 2101/02 (2013.01); C07C 2101/04 (2013.01); C07C 2101/08 (2013.01); C07C 2101/14 (2013.01); C07C 2101/18 (2013.01); C07C 2102/22 (2013.01); C07C 2102/50 (2013.01);
Abstract

The present invention relates to compounds of the formula I, wherein A, Y, Z, Rto Rand Rhave the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPAreceptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.


Find Patent Forward Citations

Loading…